• While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward
• Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value
• Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry, hence its position as a leading psychedelic wellness platform. To offer insights into the company’s growth, Matt Stang, Delic’s co-founder and chief executive officer (“CEO”), appeared on The Jesse Tee Show, a growth-mindset broadcast whose aim is to teach anyone hunting greatness the secrets to success. The show highlights top entrepreneurs, athletes, thought leaders, and creators, who walk the audience through their stories and their path to success (https://ibn.fm/Fb5PW). Mr. Stang touched on his professional background, highlighting how his senior thesis in college earned him an internship at High Times. This leading counterculture publication would later become the voice for the cannabis industry. Upon joining this enterprise, Mr. Stang became the director of its marketing and sales arm before buying the owner’s position in 2010 and becoming its driving force. Mr. Stang then grew High Times into a $20 million a year business, an achievement that he attributed to “Understanding where opportunities and people connect, how to make things win-win for all people and giving them real value” (https://ibn.fm/Fb5PW). Going on to become co-founder and CEO of Delic, headquartered in Vancouver, Stang and the company take pride in its comprehensive three-pronged ecosystem of Ketamine Wellness Centers (“KWC”), media properties, and DELIC Labs, a federally-authorized research facility. As of March 2022, the company had a market cap of $4.32 million, with a trailing 12-month (“TTM”) revenue of $3.6 million (https://ibn.fm/HaC3d). The interview also touched on the therapeutic potential of psychedelic compounds. Mr. Stang was keen to note that Delic recognizes this potential and is capitalizing on it to create value for its shareholders while also offering a solution to individuals dealing with mental health conditions. It is projected that by 2026, the psychedelic drugs market will be valued at $6.3 billion, up from $3.2 billion in 2021. This will represent a CAGR of 14.5%, mainly driven by regulatory support in the sector, widespread public awareness, and the overall growth in demand for psychedelic drug-assisted psychotherapy (https://ibn.fm/fTSah). Delic realizes this opportunity, hence its investment in research and development (“R&D”) and its push to reframe the psychedelic conversation. The company has also been strategic with its acquisitions, having closed the purchase of Seattle-based Homestead Book Company back in 2021 in a move that sought to increase the company’s psychedelic media distribution. Going forward, Delic looks to grow its intellectual property through more research. It also looks to provide education and high-quality products for the masses, particularly those struggling with mental health issues. View the full interview at https://ibn.fm/Y5ge7. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Artificial intelligence-enhanced security devices and big data collection are gaining popularity as means for strengthening companies’ footprints, particularly in response to criminal activity that can otherwise weaken operations
• Knightscope is a Silicon Valley-based company developing Autonomous Security Robots (“ASRs”) in response to America’s security needs, delivering a variety of models that observe and report on activity at client properties using powerful technological services
• Knightscope completed public listing on the Nasdaq Exchange in January 2022, enhancing awareness of its products and generating new inquiries about the nature of its services
• The company has taken note of its successes with its clients, and recently provided Q&A responses to inquiries from potential clients about the ASRs’ effectiveness

Mass-victim violence has become an almost normalized part of the American experience, so much so that it appears to attract little notice unless large numbers of the victims die. A recent report in Utah’s Deseret News noted nine mass shootings that had occurred across the country during the weekend as an example, part of the 107 such incidents that had occurred with minimal spectacle by March 23 (https://ibn.fm/FEt1t). Autonomous security robot (ASR) developer Knightscope (NASDAQ: KSCP) has been perfecting its craft in attempting to make the country safer through AI-empowered vigilance and a physical presence since April 2013, when outrage over a deadly attack on Boston Marathon runners and the tragic mass shooting of children at Connecticut’s Sandy Hook Elementary School led Knightscope’s founders to begin building robotic sentries that could monitor client properties 24/7, 365 days a year. As Knightscope’s profile has grown, particularly as a result of its trading launch on the Nasdaq exchange in January (https://ibn.fm/Mbgg7), the company has fielded a number of questions from prospective clients regarding the performance of its ASR robots and their competitiveness in a rising industry segment. The following are some of its responses to those inquiries:

1. What is the key advantage Knightscope’s technology offers to clients?
2. The number one benefit offered by Knightscope’s Autonomous Security Robots (“ASRs”) is physical deterrence. People doing bad things do not want to get caught. Knightscope provides intelligent eyes and ears on the ground. Its ASRs deliver unprecedented levels of situational awareness, actionable intelligence, and a force multiplier to augment security and public safety programs in tandem with local emergency response services. And all of this at a significant cost savings when compared with standard personnel models.
3. There’s a lot of security technology out there. What makes Knightscope stand out versus other options?
4. With 360-degree high definition video and a number of other onboard sensors that monitor, analyze, record, and report situations on the premises using powerful technological capabilities, the ASRs reduce the potential for conducting illegal activity in secrecy. Essentially, they provide an increased incentive for bad actors to avoid the risk of being caught in a crime within the vicinity of an ASR. This benefit does not exist with other security technologies.
5. What are the specific types of “robots” that Knightscope offers, and what are the differences between them?
6. – K1 Stationary Indoor/Outdoor ASR – K3 Indoor Mobile ASR – K5 Indoor/Outdoor Mobile ASR (Each robot is sized and equipped for their respective indoor, outdoor, mobile, or stationary missions.)
7. What are these robots designed to do, and what do they not do?
8. Knightscope’s ASRs are intended to augment a security program and work alongside humans. Robots are good at performing the boring, routine, and monotonous work that can sometimes be dangerous in a security setting. Humans on the other hand are great at personal service, empathy, and hands-on activities. In the ideal partnership, Knightscope’s robots observe and report, and the humans are freed up to investigate what is reported. The ASRs provide a friendly and communicative interaction with their environment, while humans are then better informed to take appropriate hands-on action if needed.
9. What kind of control does a client actually have over these security robots, and how is it done?
10. The clients have a great deal of control over their ASRs including, but not limited to, scheduling patrol routes, broadcasting messages, communicating via two-way intercom, using strobe light and patrol sounds, and stopping or parking the ASR, all of which is done through the browser-based user interface included with the service called the Knightscope Security Operations Center (“KSOC”).
11. What are some examples of how your robots are currently being used?
12. Knightscope’s ASRs are used to patrol parking lots and parking structures, banks, corporate campuses, casinos, hospitals and other healthcare facilities, transportation depots, and many other client properties from Hawaii to Rhode Island. Their uses vary from client to client, but a few examples include deterring criminal activity and vagrant trespassing, providing budget relief, improving workplace violence prevention, and watching over high-value assets.
13. How do I know how many of these robots I will need, and how expensive is it?
14. Knightscope’s Client Development team is made up of highly experienced professionals that walk each client through the process of determining needs, deciding which ASR(s) best suit those needs and then recommending appropriate placement and patrol paths to help the client resolve pain points. Knightscope’s all-inclusive service is incredibly affordable at $3 to $9 per robot per hour.
15. What evidence is there that all this technology really works better than just hiring security guards, etc.?
16. Have a look at our crime fighting wins and statistics here: https://www.Knightscope.com/crime/

As an example of client satisfaction, Huntington Park, Calif.’s, city council extended its municipal contract with Knightscope last year for an ASR that patrols a park of concern to the city, responding to the chief of police’s recommendation. Video of the discussion is available here: https://ibn.fm/5gk3q For more information about Knightscope, visit the company’s website at www.Knightscope.com, and if you are considering subscription service you can request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

• Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction
• Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials
• The company is targeting nicotine addiction in tobacco smokers
• Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products

Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is making gains in its efforts to bring novel products to clinical trial for the potential treatment of addictive behaviors such as unhealthful smoking of tobacco-derived nicotine, announcing March 24 that an Institutional Review Board (“IRB”) has granted conditional approval for a new smoking cessation trial planned this summer (https://ibn.fm/43cgH). Mydecine plans to begin patient recruitment in a multi-site Phase 2b clinical trial of its lead drug candidate MYCO-001, 99% pure psilocybin, once investigational new drug (“IND”) approval has been granted by the U.S. Food and Drug Administration (“FDA”). MYCO-001 would be used as a therapeutic, in conjunction with therapy, for nicotine-dependent individuals in partnership with Dr. Matthew Johnson of Johns Hopkins University, who will oversee the psychotherapy regimen. The planned placebo-controlled study is designed to evaluate the safety and efficacy of psilocybin-assisted psychotherapy utilizing MYCO-001, building on prior smoking cessation studies Johnson and his team conducted that showed 59% of participants who received psychedelic-assisted therapy remained abstinent from smoking at 12 months, compared to 28% of patients who received a transdermal nicotine patch, according to the company (https://ibn.fm/RE3nq). According to the Centers for Disease Control and Prevention (“CDC”), about 12.5% of the nation’s adult population currently smoked cigarettes as of 2020, amounting to about 30.8 million adults, 16 million of whom live with a smoking-related disease (https://ibn.fm/8S09q). Mydecine representatives met with the FDA last month, and are preparing their finalized IND application as well as a request for Breakthrough Therapy designation that would grant MYCO-001 the possibility of an accelerated approval process. The company plans to submit both applications in Q2 2022 and is hopeful that the FDA will green-light the effort within 30 days. The IRB’s approval is a conditional ethical review finding that will allow Mydecine to proceed once it has the FDA’s positive reply to its IND filing. “We are beyond excited to share the news of our conditional IRB approval,” CEO Josh Bartch stated in the company’s announcement (https://ibn.fm/dNVrU). “Upon the near-term clearance of our IND application, which is wholly owned by Mydecine, we will be the first commercial IND approved utilizing psilocybin for the indication of smoking cessation, and one of a small number of organizations with a commercial FDA IND approval, alongside COMPASS Pathways, MindMed, and Usona, for a Phase 2 or later stage study assessing a psychedelic compound for any indication. We have a strong patent and regulatory strategy to support this initiative as well as further subsequent approvals.” The Phase 2b study is contemplating a primary endpoint of six months, indicating it could publish data as early as Q4 2023, according to the company. “Mydecine is currently working our second-generation drugs through the clinical pipeline to replace our first generation with a more superior, more refined, more scalable second generation of psychedelic medicine,” Bartch said in a video presentation the company posted to YouTube last month (https://ibn.fm/ADxjy). “We’re looking at known efficacious MYCO-001 single molecule psilocybin that we feel is drastically better than what’s currently available on the marketplace (for treating smoking cessation).” The basis for the drug has already been established in nature, Chief Scientific Officer Rob Roscow said in the video. “Mydecine takes a very nuanced approach to drug development,” Roscow said. “As opposed to designing molecules from scratch that may or may not affect a condition of interest, we’re taking molecules from nature, such as psilocybin, that have already shown strong efficaciousness in the conditions that they’re treating or being studied in treating, and then we’re making very purposeful modifications — changes or improvements to these. By building off of the templates that are provided by nature to us, we really can be confident of the value of these molecules moving further in the pipeline.” The research-based company is also working to develop and commercialize other drug candidates, such as a patch-delivered tryptamine compound known as MYCO-004 and compounds MYCO-005 and MYCO-006 that target increased safety and stability in their respective psilocin and MDMA (Ecstasy) analogs, according to an investor presentation prepared by the company (https://ibn.fm/o7Bpl). “These molecules include enhancements we believe are critical for psychedelic medicine to become accepted and adopted into traditional medical settings,” a March 7 management statement regarding MYCO-005 added (https://ibn.fm/de821). “MYCO-005 includes a novel psilocin analog that could potentially be considered a heart-safe microdose drug by eliminating a possible known risk factor. Although microdosing has been gaining popularity in mainstream media as a possible treatment for indications such as ADHD, depression and anxiety, more research is needed to confirm the safety and efficacy of this method. We believe our MYCO-005 family of molecules are safer than what’s currently available.” A new subscription agreement for the sale of additional investor shares announced March 18 is designed to provide the company with “enhanced flexibility and access to capital should future additional financing be required, and it may be activated if and as deemed appropriate,” according to the company (https://ibn.fm/F0TEl). For more information on Mydecine Innovations Group, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

Fintech, Healthcare, pharma, technology, finance, infrastructure, and allied companies and investors are invited to attend the Virtual Growth Conference, being held on March 28-30, 2022, as a virtual event. The year 2022 opens up opportunities for traders and investors and this Virtual Growth Conference 2022 offers the perfect stage for networking and understanding the future scope of business. The Virtual Growth Conference is one of the leading investor conferences, organized by M-Vest Events, powered by the Maxim Group LLC, a leading investment bank. The group serves investors, issuers and industry stalwarts, allowing them to interact on an excellent online forum. The Virtual Growth Conference will offer executives, companies and investors a networking stage while connecting companies with potential investors. The event is organized only for members and offers a brilliant user experience. At the virtual conference, new companies, as well as established firms, can engage with investors through one-on-one discussions, presentations and fireside chats. The 3-day event offers fireside chats, panel discussions, live round tables, and Q&A with company heads moderated by Maxim Research Analysts, across a wide spectrum of business sectors featuring approximately 300 companies. Though virtual, these events offer an interactive forum for capitalists and professionals, industry stalwarts shareholders, leaders & executives from a wide range of sectors including Autonomous Vehicles, Biotech, Blockchain Technology, CBD / Cannabis, Clean Energy, Digital Media, Electric Vehicles, Financial Services, Fintech & REITS, Online Gaming & Entertainment, Healthcare, Health & Wellness, Healthcare IT, Infrastructure, Shipping and Technology / Media / Telecom. Young companies looking for potential investors can leverage this phenomenal opportunity to gain visibility and get discovered by giant firms. This Growth Conference will be held as a live streaming online conference, in keeping with the current health and safety protocols. Day 1 is dedicated to the healthcare sector, with discussions and fireside chats being held by pharma, medical and life science companies on a wide gamut of topics. On day 2, industries from the tech and finance sectors will hold presentations and fireside chats. On the last day, miscellaneous companies will come together and interact in the virtual environment of the conference. At the Growth Conference, presenting companies introduce and discuss the company goals and share insights on specific topics of relevance. These events are tailored to offer an engaging experience to a seasoned crowd of investors and executives. To learn more, please visit https://ibn.fm/cg5yX

• Cannabis product cultivator Flora Growth Corp. operates a premium growing facility in central Colombia and has received a growing list of authorizations to export its cannabis products for varied health and wellness purposes
• Flora Growth’s authorized distribution of low-THC CBD cannabis derivatives has been recently expanded to include a quota of up to 43,600 kg of products with high-THC cannabis
• Flora also reached agreement with Israel-based DNO Group to further commercialize Flora’s Mind Naturals skin care products through potential distribution outlets in Hong Kong, with plans to build into outlets in Israel and India later
• Colombia has also authorized the company to add four new genetic strains to its high-yield THC and high-yield CBD (cannabidiol) product portfolio for use in commercial products

Global cannabis brand builder Flora Growth (NASDAQ: FLGC) solidified distribution deals this month that expand the amount of high-THC (tetrahydrocannabinol) dry flower and cannabis derivative products it is permitted to export from its Colombia base of operations and open new market opportunities for its Mind Naturals skin care products in Asia and Eastern Europe. Flora Growth is an internationally focused company with all-outdoor cultivation facilities in central Colombia where growing conditions are some of the most ideal in the world. Its 100-hectare (about 247-acre) Cosechemos facility benefits from a government that is increasingly friendly to cannabis production and transportation, having legalized exportation last year of dried flower for food, textile and medicinal purposes and having established the regulations just last month (https://ibn.fm/V1QEE). On March 15, the company announced that the Colombian government’s Ministry of Health and Social Protection expanded authorization on its product exports to include not only cannabis derivative products with less than 1% of the psychoactive THC compound but also up to 43,600 kg of products with high-THC cannabis that are designed for health and wellness uses and not the recreational-use market. “With receipt of this expanded 2022 quota, we can now work towards fulfilling previous agreements, including the agreement with Artos Ltd. to send high-THC cannabis to Israel and other legal markets,” Flora’s Chief Commercial Officer Jason Warnock stated (https://ibn.fm/GOkWX). “The changes to the export quota this year represent a major milestone for Colombian exports and provide a clear pathway for the region to make a significant global impact on the cannabis industry.” The government’s Agricultural Institute (“ICA” or Instituto Colombiano Agropecuario) also authorized Flora to add four additional strains to its high-yield THC and high-yield CBD (cannabidiol) product portfolio, expanding potential commercialization opportunities for the company. In the meantime, the new distribution agreement regarding its Mind Naturals premium CBD skin care brand teams Flora with Israel-based DNO Group, a company with over 50,000 points of sale throughout Asia as part of its broad global reach. Together, the companies will use an omnichannel approach including brick and mortar retail, e-commerce and other wholesale markets to market Mind Naturals in Hong Kong with anticipated expansion to Israel and India during second-phase growth, according to the company (https://ibn.fm/XTTGJ). The agreement builds on Mind Natural’s 12-product retail launches through Walmart.com and Mexico’s Coppel, which has a network of 1,253 stores in the country (https://ibn.fm/0bRhq), and initial exports to Spain. “With quality ingredients and a thoughtful customer experience, Mind offers something different in this competitive space. We look forward to working with DNO to bring this unique offering to key markets around the world,” CEO Luis Merchan stated. For more information, visit Flora Growth’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The inflation rate in the United States for the 12 months ending February 2022 was 7.9%, the highest it has been since January 1982
• In addition to the rise in inflation, the price of gold has risen to levels not previously seen
• StraightUp Resources Inc. looks to capitalize on this growing price and looks to benefit from it given its investments in properties with a rich history of gold production

Although today there are a number of investments being touted as the best hedges against inflation, the current high rate of inflation, and its long-term prospects for continuing, together with a variety of geopolitical risks, have led investors to take another look at gold. The current inflation rate in the United States for the 12 months ending February 2022 stood at 7.9%, the highest since January 1982 (https://ibn.fm/uSmXi). In addition, the inflation-adjusted value of gold has been touching record high levels. It is further projected that the value will continue to rise given the uncertainty in Europe with the Russia-Ukraine conflict (https://ibn.fm/j6gF0). StraightUp Resources (CSE: ST) (OTCQB: STUPF) stands to be one of the beneficiaries of the growth in gold’s value. With its flagship property located in the Red Lake Mining District of Ontario, known for over 30 million ounces of historic gold production, this enterprise is set to benefit significantly from the surge in the metal’s value, and shareholders are looking for reflected growth in the company’s share price and the overall value of the enterprise. StraightUp has been committed to mineral exploration and acquiring mineral assets in North America. Its goal has been to maximize shareholder wealth through mineral discoveries at projects with the best potential, maintaining long-lasting partnerships, continued acquisitions, development, and exploration of mineral resource properties in North America. This has seen it acquire strategic properties rich in gold, including the 10,000-hectare RLX projects, sharing a common border with critical properties such as Evolution Mining, Pacton Gold, Dixie Gold, and Great Bear Resources properties. In addition, the company’s Belanger Project has seen three significant exposures of gold, copper and silver over a 2,000-hectare property, with similarly promising results showing up in the Ferdinand Gold Project and the Bear Head Gold Project. StraightUp’s management is optimistic about the future and the value that it is expected to generate. Earlier this year, the company received its early exploration permit (“PR-21-000261”) from the Ministry of Northern Development and Mine, Natural Resources and Forestry (“NDMNF”), granting it the authority to proceed with mechanized drilling and geophysical surveys (https://ibn.fm/K8jdd). The company plans to capitalize on this permit to develop and test gold targets, starting with detailed data compilation, including interpretation of the high-resolution airborne geophysical surveys conducted in 2021. With the price of gold going up, the company’s exploration efforts are slowly proving themselves invaluable. In addition, it is validating its exploration goals, and the management is confident that the investments made so far will pay off significantly as time progresses. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

SPYR Inc. (SPYR) Appoints Michael Teitelbaum and Siobhán Ellis to Subsidiary Applied Magix Inc. Advisory Board

• Both additions to the advisory board will aid SPYR’s continued effort to identify and target acquisitions to grow in the industry and expand its product offering to consumers
• Mr. Teitelbaum’s experience as the senior board integrity manager of Jazzwares will help him leverage the resources necessary to facilitate growth and grow the brand
• Ms. Ellis is an avid HomeKit user and has experience working with data in her current role at the U.K. offices of Jaguar Land Rover

Technology company SPYR (OTCQB: SPYR), dba SPYR Technologies, and its subsidiary Applied Magix Inc., which develops and resells Apple(R) compatible products for the multibillion-dollar IoT (internet of things) smart home and car markets, has announced two recent additions to the company’s advisory board — Michael Teitelbaum and Siobhán Ellis. The two additions will aid in SPYR’s continued effort to identify and target acquisitions to grow its footprint in the industry and expand its product offering to consumers, including companies developing artificial intelligence (“AI”) and smart technology products. Applied Magix’s CEO, Dr. Harald Zink, spoke on both of these additions to the company’s advisory board. “I’m genuinely excited to have Mike on our advisory board, offering us his expertise and experience. Mike’s experience in growing brands and creating growth by leveraging online resources will be invaluable on our Applied Magix journey,” Dr. Zink said (https://ibn.fm/5jEqu). Mr. Teitelbaum is the senior brand integrity manager at Jazzwares. He stated that he was beyond excited to join the advisory board of Applied Magix. “I welcome the opportunity to share my expertise and experience and guide Applied Magix to new heights!” About Ms. Ellis’s appointment, Dr. Zink said it was a great pleasure to see her on the board (https://ibn.fm/PriUg). “Siobhán has been a great help by sharing her HomeKit experience and technical insights ever since she reached out to us when our website first went live. … Siobhán will be essential as we reach out to more online influencers and look to merge and acquire more resources under the Applied Magix banner.” Ms. Ellis lives in the U.K. and utilizes HomeKit products to make her home smarter, which presents challenges as her home was built in the 1850s. She currently works in the data office for Jaguar Land Rover in the U.K. “There are so few companies out there who concentrate on Apple’s HomeKit ecosystem, and too many that end up diluting their offering to be compliant with other platforms. I particularly appreciate that as I have made my own homes smart in the last few years, both in California and now the U.K.,” Ellis said. “This experience led me to write my own blog, on that continuing journey to help others who are just starting out. I am convinced that Applied Magix has the vision to bring products to market that solve some of the difficult aspects of home automation, without compromise.” SPYR CEO Tim Matula also commented on Ms. Ellis’ appointment to the board, saying that her diverse background and focused experience complements the company’s philosophy. “Everyone here at SPYR is working as part of a cohesive team towards the same goal — building a better SPYR and bringing the best products and services to our customers.” For product information, please see the Applied Magix website at https://AppliedMagix.com or specific product sites:

• MagixDrive Wireless CarPlay Adapter – https://AppliedMagix.com/MagixDriveBundle
• HomeKit Secure Video Camera with iCloud Storage – https://AppliedMagix.com/HomeKitCamera
• Multipurpose Sensor with Alarm – https://AppliedMagix.com/HomeKitAlarmSensor
• Environment and Motion Sensor – https://AppliedMagix.com/HomeKitMotionSensor
• Window and Door Contact Sensor – https://AppliedMagix.com/HomeKitContactSensor
• MagixBlock USB DataBlocker – https://AppliedMagix.com/MagixBlock
• MagixCharge Dual USB-C Car Charger – https://AppliedMagix.com/MagixCharge

For more information about SPYR, visit the company’s website at www.SPYR.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

• Retail investment has boomed of late, with retail investors accounting for 23% of all U.S. equity market transactions in 2021
• SRAX and investor intelligence platform, Sequire, have sought to service the informational needs of a burgeoning investor community, which now numbers over 9 million
• Sequire has looked to add value through a series of investor masterclasses and a community investor newsletter, as well as an array of corporate access events focusing on all segments of the stock market
• SRAX and Sequire sought to bolster their investment offering through the acquisition of leading small and mid-cap stock specialist, LD Micro, in late 2020

At multiple times during 2021, retail investors made up a third of all U.S. stock market trading. In fact, over the past year, retail investors in the United States have on average accounted for 23% of all U.S. equity trading – more than twice the level of 2019. Effectively, that means that retail investors now possess a stock market footprint which is approximately as large as all hedge funds and mutual funds combined (https://ibn.fm/6XWyz). Meanwhile, a survey carried out by Deutsche Bank found that nearly half of those investors were venturing into the stock market for the first time. The rise of the North American retail investor base has led to a greater desire for financial information – a need which financial technology company SRAX (NASDAQ: SRAX) has sought to fulfil. During the late 1990s, a prior period marked by retail investor enthusiasm which would ultimately culminate with the dotcom boom and bust, a study carried out by Oklahoma State and Emory University found that the average retail investor was 50 years old and had around $47 thousand to play with. In contrast, today’s average investor is around 31 years old, has between $1,000 and $5,000 to invest, and is likely to be a member of an online retail investor chat forum. In fact, one particularly influential Reddit-based group currently boasts upwards of 9.4 million members, a figure which has swelled ten times over since the start of 2020. SRAX, and its investor intelligence platform, Sequire, have looked to cater to the rapidly rising population of retail, high-net-worth, and institutional investors, and their need for financial information and interaction amongst their peers. Since its inception, Sequire has seen its community swell to over nine million influential, forward-thinking investors and shareholders, firmly establishing itself as a venue where investors can congregate to learn, share and network on a wide range of industry related topics. Ranging from curating educational opportunities with leading investors and industry experts through masterclasses, to publishing a community newsletter to provide members with relevant and timely stock market and industry updates and hosting a wide array of virtual and in-person investor conferences every year, Sequire has taken it upon themselves to help their followers stay in the know and make informed investing decisions. That mission was further reinforced in late 2020, when SRAX acquired LD Micro, one of the leading data and event companies servicing the small and micro-space. Having hosted over 1,500 companies within their well-established industry events since 2008, SRAX and Sequire have sought to make LD Micro’s must-attend events the centrepiece of their conference offering; the success of that initiative was self-evident over the course of the 2021 LD Micro Main Event, which marked the first in-person conference for LD Micro in nearly two years following the onset of the pandemic. Held between October 12-14, 2021, the LD Micro Main Event attracted 139 companies in a dual, in-person and virtual format (https://ibn.fm/iILse). A recent survey carried out by Accenture revealed that 55% of wealth management consumers in the U.S. and Canada found that the financial advice they received was too generic, with 34% of all investors stating that they would increase their investments if they received a more personalized experience (https://ibn.fm/CCJd5). SRAX has increasingly sought to fulfil that role for its millions of followers, providing a vast legion of investment services, newsletters and corporate access events designed to satisfy the needs of an increasingly discerning – and active – investment community. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

On April 4-5, 2022, biopharma and medical device professionals responsible for clinical operations, data management and risk evaluation are invited to attend the live streaming of the 2nd Risk-Based Quality Management Summit. The event is organized by Dynamic Global Events (“DGE”), an educational conference company specializing in the informational and networking needs of the life science sector. The 2-day event will start with the chairperson’s opening remarks followed by keynotes on a structured change management program for RBQM success. For successful risk-based monitoring and effective implementation of clinical trials, a world-class end-to-end comprehensive risk management plan is essential. The agenda goes into extensive detail on this topic. Experts will discuss the effective methods to convince and educate shareholders on the importance of complete buy-in across the organization. They will further talk about the importance of regulatory acceptance of remote monitoring and digital technologies, and also share their expertise on how to comfortably maintain levels of risk tolerance and agility in complex clinical trials while accelerating drug development. This summit covers new approaches in mitigating risk and managing challenges to clinical trial oversight. The RBQM Summit provides up-to-date strategies on reducing the complexity and costs associated with clinical trials, cutting down the risks involved, and deriving the maximum output from the R&D budget. Companies and professionals will learn how to evaluate risks in virtual trials, understand the complexities involved, and thereafter construct a strong framework for their clinical trials. Industry leaders with robust experience will share insights on K-97-1 and the FDA’s “Decision Tree”. Attendees will also learn the spotlight benefits of AI and ML for curating unstructured data. They can leverage this platform to explore data literacy as the change agent to deliver study wide insights, and learn to plan and implement QTLs for ICH E6 (“R2”) compliance. Despite all measures, why do clinical trials fail? Join the valuable sessions at the 2nd Risk-Based Quality Management Summit to understand why studies fail and build strategies to improve trial success. To learn more, please visit https://ibn.fm/TSqRE

Clearmind (CSE: CMND) (FSE: CWY0) Management invites leaders, innovators, scientists, doctors, patients, enthusiasts, and luminaries in the psychedelic space to attend a virtual Q&A session on March 30th, focused on the potential treatment of alcohol use and binge drinking based on its psychoactive molecule MEAI. Global leaders and innovators in the psychedelic space will participate in the virtual event and discuss psychedelic therapies and treatments for excessive alcohol consumption and mental disorders. The dedicated team of experts at Clearmind is engaged in developing breakthrough treatments for binge behaviour, alcohol use disorder, binge eating and depression. Adi Zuloff-Shani, PhD, Clearmind’s Chief Executive Officer, is one of the leading speakers at the event, with over 20 years of strategic and operational leadership in the health care industry and in-depth knowledge on therapeutics development in heavily regulated environments. In addition, Shannon Smadella, Clearmind’s Community Development, will host the Q&A sessions. She has interviewed numerous innovators, doctors and luminaries in the health and wellness space. Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development, is also one of the speakers at the Clearmind Mangement event. Mark has published on the issue of drug control policy and psychedelics and has significant contribution in counselling, supervisory and management of addiction. Previously, people needing care for alcohol use disorders had only a limited range of options. At the Clearmind Management Psychedelics for Alcoholism session, influential personas and leading doctors, scientists, and professors of the psychedelic space will discuss the drug control policies, as well as offer counselling and advice on addiction, binge eating and depression. The agenda of the event is to create awareness about the potential treatment for alcohol use disorder, psychedelics and other therapies, and make them more acceptable. This event will offer a robust platform for discussions among renowned leaders about the psychedelic treatment options for binge drinking, and further, how these medicines enhance the mental state. The Clearmind Management panel will answer queries on alcohol use disorder, and eminent industry thinkers who have spent years researching the phenomenal uses of psychedelic compounds will offer their valuable opinions about the treatment of alcohol use disorder using its psychoactive molecule MEAI. Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the “Company“), a psychedelic medicine biotech company engaged in the discovery and development of novel psychedelic-derived therapeutics, recently announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd (“Aragen”) for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”) (https://ibn.fm/WkwwD). For more information, please visit https://ibn.fm/BLHsB